|Description||Azilsartan medoxomil monopotassium is an azilsartan prodrug and and an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM. It is used in the treatment of adults with essential hypertension. It inhibited cell proliferation at concentrations as low as 1 μmol/l in aortic endothelial cells in vitro. It has antiproliferative effects of azilsartan were also observed in cells lacking AT1 receptors. It was developed by Takeda Corporation. It has been listed.|
|Appearance||White or white crystalline powder|
|Synonyms||1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester potassium salt;Azilsartan MedoxoMil PotassiuM salt;Azilsartan kamedoxomil;TAK 491 monopotassium;Potassium,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-1-oxa-2-aza-4-azanidacyclopent-2-en-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate|
|Solubility||10 mM in DMSO|
|Application||Azilsartan medoxomil monopotassium is used in the treatment of adults with essential hypertension.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Quantity||Kilogram to ton|
|Current Developer||Azilsartan medoxomil monopotassium was developed by Takeda Corporation. It has been listed.|
Tranilast, also called Rizaben or Tranilastum, has anti-inflammatory and immunomodulatory effect. It binds to Aβ40 monomers and increases Aβ40 fibrillation.
PD 123177 is a Nonpeptide angiotensin type 2 receptor inhibitor. In Dec 1995, Preclinical development of it for cardiovascular disorders was began in USA.
Forasartan, a tetrazol derivative, has been found to be a angiotensin II receptor antagonist that could be effective against hypertension through influencing th...
Angiotensin I/II (1-7)
Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor, inducing vasorelaxation through release of NO and prostaglandins.
A81988 is a potent, orally active angiotensin I1 antagonist with a long duration of action whose pharmacological profile has established it as an important tool...
Eprosartan is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.
AVE 0991 is an agonist of nonpeptide Ang-(1-7) receptor Mas that has potential as a cardiovascular drug.
PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
Azilsartan (TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension.
An antagonist of angiotensin II receptor
AVE 0991 sodium salt
AVE 0991 sodium salt, is an agonist of nonpeptide Ang-(1-7) receptor Mas that has potential as a cardiovascular drug.
Olmesartan Medoxomil is a compound which is hydrolyzed to olmesartan that is a selective AT1 subtype angiotensin II receptor antagonist.
Gemopatrilat, an azepan derivative, has been found to be an angiotensin receptor as well as vasopeptidase inhibitor that was once studied against hypertension a...
Losartan, an antagonist of angiotensin II receptor, could be effective in the treatment of hypertensive. IC50: 20nM.
Cgp 48369 is a nonpeptide a angiotensin type 1 receptor antagonist originated by Novartis. Treatmenf for for Hypertension in Switzerland was discontinued in 199...
Embusartan, an oxopyridine derivative, has been found to be an angiotensin II receptor antagonist that was once studied against hypertension by Bayer.
Losartan Potassium (DuP 753)
Losartan is an angiotensin II receptor antagonist that competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. It promotes vasodilatati...
Trans-Tranilast is an antiallergic drug used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.
Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.
Tasosartan, a pyrido-pyrimidin derivative, has been found to be an angiotensin II receptor antagonist that could have probable effect against hypertension. It h...